It was January 2023. Elon Musk owned Twitter, but it wasn’t yet called X. ChatGPT had been released barely six weeks earlier.
Absci CEO Sean McClain — tall, with short, gelled hair and a beard, the kind of all-American entrepreneur who mowed lawns to buy a video game as a kid but instead bought his first truck — got up on health care’s biggest stage, the J.P. Morgan Healthcare Conference. He pitched the synthetic biology company he had founded in a tiny basement lab in 2011,…
Article Source
https://www.statnews.com/2025/02/10/ai-drug-development-claims-by-biotech-companies-absci-generate-biomedicines-questioned/
